MX2021009722A - Anticuerpos anti-trem2 y metodos para utilizarlos. - Google Patents
Anticuerpos anti-trem2 y metodos para utilizarlos.Info
- Publication number
- MX2021009722A MX2021009722A MX2021009722A MX2021009722A MX2021009722A MX 2021009722 A MX2021009722 A MX 2021009722A MX 2021009722 A MX2021009722 A MX 2021009722A MX 2021009722 A MX2021009722 A MX 2021009722A MX 2021009722 A MX2021009722 A MX 2021009722A
- Authority
- MX
- Mexico
- Prior art keywords
- trem2
- methods
- trem2 antibodies
- antibodies
- antibody
- Prior art date
Links
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 abstract 3
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 abstract 3
- 230000004913 activation Effects 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808141P | 2019-02-20 | 2019-02-20 | |
| PCT/US2020/019093 WO2020172450A1 (en) | 2019-02-20 | 2020-02-20 | Anti-trem2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009722A true MX2021009722A (es) | 2021-09-14 |
Family
ID=69844940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009722A MX2021009722A (es) | 2019-02-20 | 2020-02-20 | Anticuerpos anti-trem2 y metodos para utilizarlos. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12240902B2 (enExample) |
| EP (1) | EP3927743A1 (enExample) |
| JP (2) | JP7543290B2 (enExample) |
| KR (1) | KR20210135518A (enExample) |
| CN (1) | CN113614110B (enExample) |
| AR (1) | AR118144A1 (enExample) |
| AU (1) | AU2020226754A1 (enExample) |
| BR (1) | BR112021015656A2 (enExample) |
| CA (1) | CA3130086A1 (enExample) |
| CL (1) | CL2021002206A1 (enExample) |
| CO (1) | CO2021012230A2 (enExample) |
| EA (1) | EA202192294A1 (enExample) |
| EC (1) | ECSP21069105A (enExample) |
| IL (1) | IL285651A (enExample) |
| MA (1) | MA55025A (enExample) |
| MX (1) | MX2021009722A (enExample) |
| PE (1) | PE20211979A1 (enExample) |
| PH (1) | PH12021552002A1 (enExample) |
| SG (1) | SG11202108734VA (enExample) |
| TW (1) | TWI879756B (enExample) |
| WO (2) | WO2020172457A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| EA202191650A1 (ru) * | 2018-12-18 | 2021-10-22 | Бёрингер Ингельхайм Ио Канада Инк. | Flt3 агонистические антитела и их применения |
| EP3927743A1 (en) | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| KR20220131246A (ko) * | 2020-01-13 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 항-trem2 항체 및 이의 사용 방법 |
| EP4337317A1 (en) * | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Agonists of trem2 |
| KR20240149428A (ko) | 2022-02-23 | 2024-10-14 | 알렉터 엘엘씨 | 항-trem2 항체의 사용 방법 |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| EP4499693A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| EP4658684A1 (en) | 2023-01-30 | 2025-12-10 | ISAR Bioscience GmbH | Human anti-trem2 antibody for treating neurodegenerative disorders |
| WO2025032071A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| TW202515919A (zh) | 2023-09-01 | 2025-04-16 | 比利時商艾托斯比利時公司 | 抗ｔｒｅｍ２抗體及使用方法 |
| WO2025106361A1 (en) * | 2023-11-15 | 2025-05-22 | Merck Sharp & Dohme Llc | Human nectin-4 binders |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| WO2010079039A1 (en) | 2009-01-06 | 2010-07-15 | Nestec S.A. | Processing of macronutrients |
| KR101579771B1 (ko) | 2009-03-05 | 2015-12-28 | 애브비 인코포레이티드 | Ｉｌ-17 결합 단백질 |
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| JPWO2012176779A1 (ja) * | 2011-06-20 | 2015-02-23 | 協和発酵キリン株式会社 | 抗ｅｒｂＢ３抗体 |
| EP2992013B1 (en) | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| US11261262B2 (en) | 2013-09-03 | 2022-03-01 | Novimmune Sa | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN105218669A (zh) | 2014-06-10 | 2016-01-06 | 河北翰林生物科技有限公司 | 制备抗人r47h-trem2突变体的人单克隆抗体的方法 |
| US20170240631A1 (en) * | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA2961950A1 (en) | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| JP6996979B2 (ja) | 2015-03-31 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 三量体ｔｎｆファミリーリガンドを含む抗原結合分子 |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| WO2017147509A1 (en) | 2016-02-25 | 2017-08-31 | Marco Colonna | Compositions comprising trem2 and methods of use thereof |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| AU2017300040A1 (en) | 2016-07-22 | 2019-01-24 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | TREM2 cleavage modulators and uses thereof |
| CN118271442A (zh) | 2016-12-23 | 2024-07-02 | 蓝鳍生物医药公司 | 抗sez6l2抗体和抗体药物缀合物 |
| WO2018134815A2 (en) | 2017-01-17 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| FI3583120T3 (fi) | 2017-02-17 | 2023-01-13 | Muunneltuja transferriinireseptoria sitovia polypeptidejä | |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| JP2020530986A (ja) | 2017-07-27 | 2020-11-05 | ノバルティス アーゲー | シェダーゼ耐性ｔｒｅｍ２変異体 |
| DK3601358T5 (da) | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2019032955A1 (en) | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| CA3076369A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| WO2019079529A1 (en) | 2017-10-17 | 2019-04-25 | The Translational Genomics Research Institute | TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| KR102860409B1 (ko) | 2017-12-12 | 2025-09-16 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체 및 관련 방법 |
| WO2019140050A1 (en) | 2018-01-10 | 2019-07-18 | Denali Therapeutics Inc. | Transferrin receptor-binding polypeptides and uses thereof |
| JP7517997B2 (ja) | 2018-06-18 | 2024-07-17 | デナリ セラピューティクス インコーポレイテッド | プログラニュリンを含む融合タンパク質 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| SG11202101273VA (en) | 2018-08-16 | 2021-03-30 | Denali Therapeutics Inc | Engineered bispecific proteins |
| KR20210074279A (ko) | 2018-08-22 | 2021-06-21 | 데날리 테라퓨틱스 인크. | 항-her2 폴리펩타이드 및 이의 사용방법 |
| KR20210057113A (ko) | 2018-09-11 | 2021-05-20 | 워싱턴 유니버시티 | 항-trem-2 작용제 항체 |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| WO2020112889A2 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
| MA54450A (fr) | 2018-12-10 | 2021-10-20 | Denali Therapeutics Inc | Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation |
| CA3122725A1 (en) | 2018-12-10 | 2020-06-18 | Mor Research Applications | Trem2 antibodies and uses thereof |
| CA3120875A1 (en) | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
| EP3927743A1 (en) | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| MX2021011612A (es) | 2019-04-03 | 2021-12-10 | Denali Therapeutics Inc | Formulaciones de moleculas proteicas que comprenden iduronato 2-sulfatasa. |
| AU2020411480B2 (en) | 2019-12-23 | 2023-12-21 | Denali Therapeutics Inc. | Progranulin variants |
| KR20220131246A (ko) | 2020-01-13 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 항-trem2 항체 및 이의 사용 방법 |
| TWI890727B (zh) | 2020-01-13 | 2025-07-21 | 美商戴納立製藥公司 | 抗trem2 抗體及其使用方法 |
| EP4100419A4 (en) | 2020-02-07 | 2024-05-29 | Denali Therapeutics Inc. | METHODS OF TREATING HUNTER SYNDROME |
| CA3170338A1 (en) | 2020-02-19 | 2021-08-26 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| MA71661A (fr) | 2020-10-14 | 2025-05-30 | Denali Therapeutics Inc. | Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées |
-
2020
- 2020-02-20 EP EP20711737.5A patent/EP3927743A1/en active Pending
- 2020-02-20 SG SG11202108734VA patent/SG11202108734VA/en unknown
- 2020-02-20 WO PCT/US2020/019104 patent/WO2020172457A1/en not_active Ceased
- 2020-02-20 CA CA3130086A patent/CA3130086A1/en active Pending
- 2020-02-20 AR ARP200100461A patent/AR118144A1/es unknown
- 2020-02-20 BR BR112021015656-9A patent/BR112021015656A2/pt unknown
- 2020-02-20 PE PE2021001367A patent/PE20211979A1/es unknown
- 2020-02-20 WO PCT/US2020/019093 patent/WO2020172450A1/en not_active Ceased
- 2020-02-20 PH PH1/2021/552002A patent/PH12021552002A1/en unknown
- 2020-02-20 MX MX2021009722A patent/MX2021009722A/es unknown
- 2020-02-20 CN CN202080015804.2A patent/CN113614110B/zh active Active
- 2020-02-20 EA EA202192294A patent/EA202192294A1/ru unknown
- 2020-02-20 AU AU2020226754A patent/AU2020226754A1/en active Pending
- 2020-02-20 MA MA055025A patent/MA55025A/fr unknown
- 2020-02-20 TW TW109105560A patent/TWI879756B/zh active
- 2020-02-20 KR KR1020217028927A patent/KR20210135518A/ko active Pending
- 2020-02-20 JP JP2021548668A patent/JP7543290B2/ja active Active
-
2021
- 2021-08-16 IL IL285651A patent/IL285651A/en unknown
- 2021-08-16 US US17/402,986 patent/US12240902B2/en active Active
- 2021-08-16 US US17/403,406 patent/US20220073609A1/en not_active Abandoned
- 2021-08-18 CL CL2021002206A patent/CL2021002206A1/es unknown
- 2021-09-17 CO CONC2021/0012230A patent/CO2021012230A2/es unknown
- 2021-09-17 EC ECSENADI202169105A patent/ECSP21069105A/es unknown
-
2024
- 2024-08-21 JP JP2024139367A patent/JP2024164116A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020226754A1 (en) | 2021-09-16 |
| US20220073609A1 (en) | 2022-03-10 |
| US20220119522A1 (en) | 2022-04-21 |
| AR118144A1 (es) | 2021-09-22 |
| TW202045543A (zh) | 2020-12-16 |
| TWI879756B (zh) | 2025-04-11 |
| CN113614110A (zh) | 2021-11-05 |
| MA55025A (fr) | 2021-12-29 |
| BR112021015656A2 (pt) | 2021-10-05 |
| CL2021002206A1 (es) | 2022-04-22 |
| PE20211979A1 (es) | 2021-10-05 |
| WO2020172450A1 (en) | 2020-08-27 |
| WO2020172457A1 (en) | 2020-08-27 |
| CO2021012230A2 (es) | 2021-09-30 |
| ECSP21069105A (es) | 2021-11-18 |
| PH12021552002A1 (en) | 2022-09-19 |
| CN113614110B (zh) | 2025-03-25 |
| KR20210135518A (ko) | 2021-11-15 |
| US12240902B2 (en) | 2025-03-04 |
| CA3130086A1 (en) | 2020-08-27 |
| SG11202108734VA (en) | 2021-09-29 |
| JP2022520868A (ja) | 2022-04-01 |
| EP3927743A1 (en) | 2021-12-29 |
| EA202192294A1 (ru) | 2021-12-24 |
| JP7543290B2 (ja) | 2024-09-02 |
| JP2024164116A (ja) | 2024-11-26 |
| IL285651A (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009722A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| CO2022009744A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
| CL2021001368A1 (es) | Anticuerpos biespecíficos anti-pd-l1/anti-4-1bb y usos de los mismos | |
| CL2022001886A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| UY37758A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| PA8645301A1 (es) | Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina | |
| CO2020012360A2 (es) | Anticuerpos multiespecíficos y utilización de los mismos | |
| UY37083A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso | |
| BR112021021645A2 (pt) | Anticorpos anti-hvem e uso dos mesmos. | |
| MX2021004284A (es) | Anticuerpos anti-npr1 y usos de los mismos. | |
| MX2022007158A (es) | Anticuerpos anti-ly6g6d y metodos de uso. | |
| AR122930A1 (es) | Anticuerpos de pre-direccionamiento y métodos de uso | |
| CO2019009035A2 (es) | Proteínas de unión al receptor de glucagón y métodos para usarlas | |
| MX2025005542A (es) | Moléculas antagonistas de fcrn y métodos de uso de estas | |
| CL2025002112A1 (es) | Anticuerpo anti-npr1; método de producción; y su uso. | |
| ECSP22056627A (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
| CL2022000752A1 (es) | Molécula de unión específica para lif y uso de la misma | |
| MX2020008114A (es) | Cuantificacion y modelado de atributos de calidad de anticuerpos monoclonales terapeuticos. | |
| WO2018176030A3 (en) | Antibodies and immunoassays for detection of bmp-15 and gdf-9 isoforms | |
| EA202192396A1 (ru) | Способы и композиции для лечения рака | |
| CO2025010348A2 (es) | Anticuerpos anti-pdl1 y métodos de uso |